KLA: Why AI Agents Need Evidence Before They Reach Clinical and PV Workflows

Overview: How KLA’s AI-Driven Governance, Risk & Compliance Platform Transforms Life Sciences AI Operations

KLA is a runtime governance and risk-control platform for AI agents used in life-sciences workflows, designed to apply policy checkpoints, human approvals and continuous evidence capture while an AI-enabled process runs. It addresses the gap between rapid AI prototyping and the slower work of establishing reliable oversight, traceability and decision review for use in clinical research, pharmacovigilance, medical–legal–regulatory review, manufacturing quality and dossier-preparation workflows.

The platform converts organisational procedures and validation plans into machine-readable rules that can govern an agent’s access, actions and escalation paths. It records source materials, generated outputs, policy decisions and human interventions in an evidence bundle, allowing teams to review how a workflow reached a given outcome. In a pharmacovigilance context, for example, KLA can sit around an existing agent that processes adverse-event narratives, routing defined higher-risk decisions to reviewers rather than replacing the underlying safety system.

For operations teams, the intended benefit is to make controlled AI deployment less dependent on assembling retrospective documentation after a pilot is built. Continuous monitoring and decision lineage can reduce the manual effort required to review agent activity, while human checkpoints help concentrate expert attention on exceptions and consequential actions. Its approach is particularly relevant for organisations that want to introduce AI into established clinical, safety, or quality workflows while retaining visibility into how automated steps affect operational decisions.

What is KLA?

KLA is a runtime governance platform for AI agents in life-sciences workflows, including clinical protocol drafting, pharmacovigilance case triage, medical–legal–regulatory review, GMP quality monitoring and regulatory dossier preparation. It targets pharmaceutical, biotechnology, and MedTech organisations seeking controls around AI deployment in clinical, safety, quality, and regulatory operations.

KLA applies policy-as-code checkpoints, least-privilege access and human approval routing during agent execution, then records decision lineage and tamper-evident evidence bundles. Its stated approach is to govern existing AI agents rather than build the underlying clinical or pharmacovigilance agent, with documentation designed to support quality, audit and validation review.

Why Do Leading Healthcare Teams Trust KLA?

• KLA states that it provides runtime controls for AI agents used in clinical, pharmacovigilance, quality and regulatory workflows, including policy checkpoints and human approval routing.

• The platform says it produces cryptographically verifiable evidence bundles containing decision lineage, source citations, policy logs, approval records and integrity manifests.

• KLA states that its evidence approach supports traceability and ALCOA+ data-integrity principles for regulated life-sciences workflows.

• KLA maps platform controls to 21 CFR Part 11, EU Annex 11, GxP, the EU AI Act, HIPAA and GDPR; these are vendor-stated mappings, not a statement of certification or regulator approval.

• KLA’s security page states that ISO 27001 controls have been implemented, while an independent audit is planned; it does not state that the company is ISO 27001 certified.

• The company states that it has mapped safeguards to the HIPAA Security Rule and acts as a GDPR Article 28 data processor; buyers should independently assess contractual and technical applicability.

• KLA describes zero-trust architecture, AES-256 encryption at rest, TLS 1.3 encryption in transit, customer-managed encryption keys, multi-factor authentication and SAML/OIDC identity integration.

• The company states that its software supply-chain controls include signed images, dependency vulnerability scanning, software bills of materials and a SLSA Level 3 build pipeline.

• KLA is a member of NVIDIA Inception and states that it is supported by MonacoTech, Monaco’s technology incubator.

• No healthcare-provider partnership, life-sciences strategic partnership, acquisition, merger or ownership change was specified in the reviewed company materials.